Novartis (NVS) Releases Positive Data On Ultibro Breezhaler

By Zacks Investment ResearchStock MarketsMay 15, 2016 09:43PM ET

www.investing.com/analysis/%D0%9A%D1%80%D0%B0%D1%82%D0%BA%D0%B8%D0%B9-%D0%B0%D0%BD%D0%B0%D0%BB%D0%B8%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B9-%D0%BE%D0%B1%D0%B7%D0%BE%D1%80-%D1%80%D1%8B%D0%BD%D0%BA%D0%B0-%D1%81%D1%8B%D1%80%D1%8C%D1%8F-200130161

Novartis (NVS) Releases Positive Data On Ultibro Breezhaler

By Zacks Investment Research | May 15, 2016 09:43PM ET

Saved. See Saved Items.

This article has already been saved in your Saved Items

NOVN

+2.35%

Add to/Remove from Watchlist

PFE

+0.32%

Add to/Remove from Watchlist

JNJ

+1.20%

Add to/Remove from Watchlist

ABT

+0.21%

Add to/Remove from Watchlist

Novartis AG (NYSE:NVS) announced results from the head-to-head randomized, double-blind, non-inferiority FLAME study on Ultibro Breezhaler. The trial compared the efficacy of once-daily Ultibro Breezhaler 110/50 mcg to twice-daily Seretide 50/500 mcg in reducing chronic obstructive pulmonary disease (COPD) exacerbations. Results were published in the New England Journal of Medicine.

The FLAME study met its primary endpoint. Results from the study showed consistent superiority of Ultibro Breezhaler over Seretide across exacerbation outcomes, lung function and health-related quality of life in COPD patients.

Data also demonstrated that Ultibro Breezhaler was effective in reducing the rate and prolonging the time to the first moderate or severe exacerbation, when compared to Seretide.

We note that Ultibro Breezhaler 110/50 mcg was approved in Europe in 2013 as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. The latest results from the FLAME trial bode well for the drug.

The combination was also approved in the U.S. under the name Utibron Neohaler in Oct 2015. Novartis’ COPD portfolio currently comprises Ultibro Breezhaler, Seebri Breezhaler and Onbrez Breezhaler/Arcapta Neohaler, which generated combined sales of $0.6 million in 2015, up 19% from 2014.

Approval of new drugs and label expansion of existing ones bode well for Novartis as it has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec. Additionally, its oncology drugs are facing competition from immuno-oncology therapies. Moreover, its Alcon segment is facing a decline in surgical equipment sales in the U.S. and emerging markets.

Novartis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Pfizer Inc. (NYSE:PFE) , Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT) . All three stocks sport a Zacks Rank #2 (Buy).

PFIZER INC (PFE): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

ABBOTT LABS (ABT): Free Stock Analysis Report

Original post

Zacks Investment Research

NVIDIA Earnings: Can Blackwell Chips Provide Tailwind? By Dave Kovaleski - Feb 25, 2025

The markets have been sluggish this week as investors hope for a jolt later in the week when AI juggernaut NVIDIA Corporation (NASDAQ:NVDA) reports fourth quarter and year-end...

3 Dividend-Paying Stocks Bucking the Market’s Trend By Ryan Hasson - Feb 25, 2025

On Friday, a wave of selling pressure swept across the US equity markets, leaving a trail of losses. The S&P 500 closed down 1.7%, the DOW slid 1.69%, and the NASDAQ tumbled a...

Palantir: Down 30% This Week, Is It Time to Flee the High-Flying... By Alessandro Bergonzi - Feb 25, 2025 6

Palantir remains highly valued with a 460x P/E ratio and a 42.5x P/B ratio, far above its peers. The stock's beta of 2.81 signals high volatility, meaning sharp moves in both...

Add a Comment

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:

Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
Only English comments will be allowed.
Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I have read Investing.com's comments guidelines and agree to the terms described.

I Agree

Write your thoughts here

Are you sure you want to delete this chart?

Delete Cancel

Post

Post also to:

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

<div id="comment">
				<div class="comment js-comment" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
    <div class="mainComment js-content">
       <div class="commentInnerWrapper">
        <a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody">
                					<span class="commentUsername">
                    	<a href="{userLink}" class="js-user-link js-user-name">{username}</a>
					</span>
                                <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
                <div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

<div class="js-option addRow follow">
            <div class="js-follow-post-button" data-reg_ep="follow comment">
                <span class="alertfollowIcon middle"></span>Follow this post            </div>
            <div class="js-unfollow-post-button displayNoneImp">
                <span class="alertUnfollowIcon middle"></span>Unfollow this post            </div>
        </div>

<div class="addRow js-option save"  data-reg_ep="save comment">
		<a href="javascript:void(0);" class="js-save-item-btn" data-item-type="comments" data-item-id="{commentID}">
			<i class="saveItemBigIcon middle"></i>
			Save		</a>
	</div>
	<div class="addRow saveItemsConfirmation noHover displayNone js-saveItemResult">
		
<div class="content js-saveItemSuccess displayNone">
	<span class="mediumGreenSuccessIcon"></span><span>Saved. See <a href="/members-admin/saved-items" target="_blank">Saved Items</a>.</span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
<div class="content js-saveItemAlreadySaved saveItemAlreadySaved displayNoneImp">
	<span>This comment has already been saved in your <a href="/members-admin/saved-items" target="_blank">Saved Items</a></span>
	<a href="javascript:void(0);" class="bugCloseIcon js-close"></a>
</div>
	</div>

<div class="addRow shareButtons js-sharePopup displayNone">
			<div class="js-shareComment"><span class="js-shareCommentSpan"></span></div>
		</div>
	</div>
</div>
                 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div>             </div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="commentBigChart js-comment-chart" onclick="openViewChartPopup('{commentID}')">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

<div class="reportComment js-flag float_lang_base_2">
                            <a href="javascript:void(0);" id="commentFlag_{commentID}">
                                <span class="reportCommentIcon middle"></span><span class="inlineblock middle">Report</span>
                            </a>
                        </div>
                    				</div>
					</div>
	   </div>
	</div>
	</div>			</div>
			<div id="reply">
				
    <div class="commentReply js-comment js-comment-reply" data-comment-id="{commentID}" id="comment-{commentID}" data-user-id="">
		<div class="commentInnerWrapper"><a href="{userLink}" class="js-user-link"><img src="{userImage}" width="33" height="33" alt="{usernameAlt}" class="img" onerror="this.src='https://i-invdn-com.investing.com/defaultUserMaleTmp.png';"></a><div class="commentBody js-content">
            				<span class="commentUsername">
					<a href="{userLink}" class="commentUsername js-user-link js-user-name" onMouseOver="">{username}</a>
				</span>
                        <span class="js-date" comment-date="{dateFormat}" comment-date-formatted="{dateFormatted}" title="{dateTitle}">Just Now</span>
			 <div class="commentAuthor js-comment-by-author"><span class="commentAuthorIcon"></span>Author's response</div> 			<div class="commentDropDown js-commentDropDownWrapper " data-user-id="" data-cid="{commentID}">
	<a href="javascript:void(0);" class="threeDotsIconSmall js-thinDropdownArrow"></a>
	<div class="tooltipPopup commentActionsPop noHeader js-commentDropDownOptions displayNone">
		<div class="addRow js-option share">
			<a href="javascript:void(0);" class="js-commentSharePopup" data-cid="{commentID}" data-curl="{commentLink}"><span class="smallShareIcon middle"></span>Share</a>
		</div>

</div>
		<div id="commentText-{commentID}" class="js-text-wrapper commentText withImage">
							<div id="commentBigChart{commentID}" class="replyBigChart displayNone js-comment-chart">
					<img src="https://d1-invdn-com.investing.com/comments_images/{commentImage}" alt="{commentAlt}">
					<i class="newMagnifyChartIcon"></i>
				</div>
				<span id="commentSmallChart{commentID}" class="commentSmallChart pointer js-comment-chart" onclick="openViewChartPopup('{commentID}')">
                    <img src="https://d1-invdn-com.investing.com/comments_images/{commentImageSmall}" width="116" height="52" alt="{commentAlt}">
                    <span class="chartMagnifyOverlay displayNone"></span>
                    <span class="searchGlassIcon chartMagnify displayNone"></span>
                </span>
						<span class="js-text">{commentContent}</span>
			<div class="clear"></div>
							<div class="commentButtons js-not-master-user">
					<a href="javascript:void(0)" class="reply js-reply-btn" data-real-parent-id="{commentID}" data-to-user-name="{username}" data-to-user-id="">Reply</a>
					<div class="inlineblock likeDislikeBox js-like-dislike-box" data-item-id="{commentID}">
	<input class="js-like-checkbox" type="checkbox" name="option" value="Yes" id="like_{commentID}">
	<label for="like_{commentID}" class="like" title="I agree"></label>
	<span class="numOfLikes js-like-count lighterGrayFont">0</span>
	<input class="js-dislike-checkbox" type="checkbox" name="option" value="No" id="dislike_{commentID}">
	<label for="dislike_{commentID}" class="dislike" title="I disagree"></label>
	<span class="numOfDislikes js-dislike-count lighterGrayFont">0</span>
</div>

Are you sure you want to delete this chart?

Delete Cancel

Post

Replace the attached chart with a new chart ?

Replace Cancel

1000

Comment Guidelines

Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.

Please wait a minute before you try to comment again.

I feel that this comment is:

Spam

Offensive

Thank You!

Your report has been sent to our moderators for review

Central Banks

Interest Rates

Next Meeting

FED

4.50%

Mar 19, 2025

ECB

2.90%

Mar 06, 2025

BOE

4.50%

Mar 20, 2025

SNB

0.50%

Mar 20, 2025

RBA

4.10%

Apr 01, 2025

BOC

3.00%

Mar 12, 2025

RBNZ

3.75%

Apr 09, 2025

BOJ

0.50%

Mar 19, 2025

CBR

21.00%

Mar 21, 2025

RBI

6.25%

Mar 10, 2025

PBOC

3.10%

BCB

13.25%

Mar 19, 2025

US 30	43,551.0	+89.1	+0.20%
US 500	5,952.8	-30.7	-0.51%
Dow Jones	43,548.47	+87.26	+0.20%
S&P 500	5,952.13	-31.36	-0.52%
Nasdaq	19,064.08	-222.84	-1.16%
S&P 500 VIX	19.67	+0.69	+3.64%
Dollar Index	106.290	-0.219	-0.21%

Crude Oil WTI	68.83	-1.87	-2.64%
Brent Oil	72.36	-1.95	-2.62%
Natural Gas	4.034	+0.052	+1.31%
Gold	2,918.14	-45.06	-1.52%
Silver	31.835	-0.768	-2.36%
Copper	4.5440	-0.0195	-0.43%
US Soybeans	1,030.25	+1.25	+0.12%

U.S. 10Y	4.297	-0.096	-2.19%
U.S. 30Y	4.565	-0.084	-1.81%
U.S. 5Y	4.138	-0.092	-2.17%
U.S. 3M	4.292	-0.007	-0.16%
US 10Y T-Note	110.47	+0.59	+0.54%
Euro Bund	132.50	+0.66	+0.50%
10-2 Yield Spread	22.59	-0.34	-1.48%

Apple	248.67	+1.57	+0.64%
Alphabet A	176.62	-2.63	-1.47%
Tesla	304.00	-26.53	-8.03%
Amazon.com	208.51	-4.21	-1.98%
Netflix	970.63	-17.85	-1.81%
Meta Platforms	656.35	-11.78	-1.76%
Bank of America	43.73	-0.73	-1.64%

Novartis (NVS) Releases Positive Data On Ultibro Breezhaler

Related Articles